Zobrazeno 1 - 10
of 30
pro vyhledávání: ''
Autor:
Paul Delmar, Anny Yue Yin, David S. Shames, Wolfram Brugger, Martin Reck, Gaelle Klingelschmitt, Eng Huat Tan, Tudor Ciuleanu, Olivia Spleiss, Federico Cappuzzo, Barbara Klughammer, Tony Mok, Lin Wu
Publikováno v:
Journal of Thoracic Oncology. 11:545-555
Introduction Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth factor receptor gene ( EGFR ) predict activity of EGFR tyrosine kinase inhibitors, including erlotinib; however, the ability of less common EGFR mutations to predic
Autor:
Fumitomo Sato, Kazutoshi Shibuya, Naoshi Kikuchi, Takashi Makino, Akira Iyoda, Fumiaki Ishida, Nao Hirota, Kazutoshi Isobe, Yoshinobu Hata, Keishi Sugino, Sakae Homma, Kyohei Kaburaki, Susumu Sakamoto, Hajime Otsuka, Hiroshi Kobayashi, Keita Sato, Yujiro Takai, Naobumi Tochigi, Go Sano
Publikováno v:
Journal of Thoracic Oncology
Background: Germline alterations in the proapoptotic protein Bcl-2–like 11 (BIM) can have a crucial role in tumor response to treatment. To determine the clinical utility of detecting BIM deletion polymorphism in non–small-cell lung cancer positi
Publikováno v:
Journal of Thoracic Oncology. 8:1163-1169
Introduction: The Wilms' tumor gene ( WT1 ) has been identified as an oncogene in many malignant diseases, and aberrant WT1 expression has been linked to development, progression, and prognosis of non–small-cell lung cancer (NSCLC). We sought to in
Autor:
David M. Jackman, Mizuki Nishino, Geoffrey R. Oxnard, Bruce E. Johnson, Peter C. Lo, Mohit Butaney, Neal I. Lindeman, Pasi A. Jänne, Suzanne E. Dahlberg
Publikováno v:
Journal of Thoracic Oncology. 8(2):179-184
Introduction Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of resp
Autor:
Hannah M. Canepa, Alexandra S. Bailey, Mark S. Huberman, Norihiro Yamaguchi, Sohei Nakayama, Susumu Kobayashi, Michael A. Goldstein, Daniel B. Costa
Publikováno v:
Journal of Thoracic Oncology. 8(1):118-122
Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This is the case of the most common EGFR mutations affecting exon 18
Autor:
Meng-Feng Tsai, Chen-Tu Wu, Shang-Gin Wu, Pin-Fei Wei, Jin-Yuan Shih, Tzu-Hsiu Tsai, Chih-Hsin Yang, Chong-Jen Yu, Yih-Leong Chang, Pan-Chyr Yang
Publikováno v:
Journal of Thoracic Oncology. 7:993-1000
Introduction Tumor tissue is often not obtainable or suitable for molecular-based epidermal growth factor receptor ( EGFR ) mutational analysis in advanced non–small-cell lung cancer (NSCLC). This retrospective and single-institution study was cond
Autor:
Filippo de Braud, Gianluca Spitaleri, Massimo Barberis, Lorenzo Spaggiari, Tommaso De Pas, M. Giovannini, Chiara Catania, Caterina Fumagalli, Angelo Delmonte, Francesca Toffalorio, Michela Manzotti
Publikováno v:
Journal of Thoracic Oncology. 6(11):1895-1901
Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib. Although the "common" EGFR mutations, such as the L858R point mutat
Autor:
Paul Germonpré, Robert Gosselin, Lionel Bosquée, Yoshiro Kishi, Jan P. van Meerbeeck, Paul De Vuyst, Kristiaan Nackaerts, Eliane Kellen, Walter De Wever, Joris R. Delanghe, Kevin Hollevoet, Catherine Legrand
Publikováno v:
Journal of thoracic oncology
Introduction: Soluble mesothelin (SM), megakaryocyte potentiating factor (MPF), and osteopontin (OPN) are blood biomarkers of mesothelioma. This study evaluates their use as markers of response to therapy and outcome. Methods: Sixty-two patients with
Autor:
Maija R.J. Kohonen-Corish, Catherine Kennedy, Christina I. Selinger, Dessislava Mladenova, Brian C. McCaughan, Wendy A Cooper, Sam Al-Sohaily, Clare Stirzaker, Laurent Pangon
Publikováno v:
Journal of Thoracic Oncology. 6(7):1179-1189
IntroductionLung cancer is the leading cause of cancer-related mortality and requires more effective molecular markers of prognosis and therapeutic responsiveness. Special AT-rich binding protein 1 (SATB1) is a global genome organizer that recruits c
Autor:
Christoph zur Verth, Pierre Tennstedt, Ronald Simon, Christian R. Habermann, Guido Sauter, E. Laack, Tobias Grob, Ina Thöm, Marc Regier, Carsten Bokemeyer, Birte Andritzky
Publikováno v:
Journal of Thoracic Oncology. 6:199-202
Miliary pattern of pulmonary metastases is a rarity in patients with lung cancer. We report five cases of patients with a never-smoking adenocarcinoma of the lung with such a pattern of metastases. In the tumor cells of all five patients, epidermal g